Lilly agrees to buy Calytrix Bio for up to $1.5 billion
Life Sciences
Monday, November 16, 2026
- Updated Nov 16, 2026 10:50
Eli Lilly has agreed to acquire Calytrix Bio, a company developing precision therapies for myeloproliferative neoplasms, for up to $1.5 billion in cash, Calytrix said on Monday.
Why it matters: The deal adds a preclinical blood cancer programme to Lilly's work in the field and extends a run of acquisitions that BioPharma Dive puts at more than $30 billion across 15 company purchases this year.
Data as of Calytrix Bio announcement of November 16, 2026, read in full on PR Newswire; deal terms are the company's own, corroborated by Reuters and BioPharma Dive reporting the same day. Developing item.
Eli Lilly has agreed to acquire Calytrix Bio, a Wellesley Hills, Massachusetts company developing precision therapies for myeloproliferative neoplasms, for up to $1.5 billion in cash, Calytrix said on Monday. The price includes an upfront payment and later payments tied to clinical and regulatory milestones, and the company did not disclose the size of the upfront payment.
Calytrix’s lead asset is a preclinical biparatopic antibody aimed at mutant calreticulin, the driver of essential thrombocythemia and myelofibrosis in the patients it targets, designed to deplete the mutant clone while sparing normal tissue. Calytrix was founded in 2025 by J.P. Morgan Life Sciences Private Capital, with a Series A co-led by Westlake BioPartners and a Series B led by Avoro Ventures.
Sources
- Calytrix Bio enters an agreement to be acquired by Lilly to advance outcomes for patients living with essential thrombocythemia and myelofibrosis - Calytrix Bio, via PR Newswire - 2026-11-16
- Lilly adds to buyout streak with $1.5B purchase of startup Calytrix - BioPharma Dive - 2026-11-16